Clinical Trials Logo

Congenital Heart Surgery clinical trials

View clinical trials related to Congenital Heart Surgery.

Filter by:
  • None
  • Page 1

NCT ID: NCT04945694 Not yet recruiting - Pediatric Patients Clinical Trials

Pain Management of Pecto-intercostal Fascial Block Versus Intravenous Fentanyl After Pediatric Cardiac Surgery

Start date: August 2021
Phase: N/A
Study type: Interventional

Cardiac surgical patients often experience significant postoperative pain at the median sternotomy site. In pediatric cardiac surgery, the recommended pre bypass dose of fentanyl to blunt the hemodynamic and metabolic stress response is 25-50 µg/kg Today lower doses are often used in order to achieve early extubation at such doses there is no guarantee that the stress response is completely abolished one way to overcome this problem is the use of the local anesthetic technique Regional anesthetic techniques reduce pain for up to 24 hours after cardiac surgery in children. Pectointercostal fascial block was first described by de la Torre in patients undergoing breast surgery. This novel technique blocks the anterior cutaneous nerve which is a branch of the intercostal nerve that gives sensory supply to the skin.

NCT ID: NCT04234906 Not yet recruiting - Clinical trials for Congenital Heart Surgery

Prevention of Post-Operative Cardiac Arrhythmias

POCA
Start date: January 2023
Phase: Phase 4
Study type: Interventional

Aim 1: Primary Prevention of Post-operative Cardiac Arrhythmias 1. To evaluate the efficacy of dexmedetomidine vs. the combination of Magnesium Sulfate and dexmedetomidine for the prevention of post-operative cardiac arrhythmias in children and young adults undergoing open heart surgical repair for congenital or acquired heart disease using cardiopulmonary bypass. Dexmedetomidine is currently being administered to almost all patients after coming off cardiopulmonary bypass and in the CICU. For this aim, the investigator will be comparing dexmedetomidine administered alone or in combination with Magnesium Sulfate. 2. To evaluate medication safety based on the frequency of Serious Adverse Events (SAEs) and Adverse Events (AEs) Aim 2: Secondary treatment of those Patients that develop a clinically significant arrhythmia despite having received either Dexmedetomidine alone or Magnesium Sulfate with Dexmedetomidine at the time of cardiac surgery 1. To evaluate the efficacy of intravenous (IV) Amiodarone vs. IV Procainamide for the control of postoperative cardiac arrhythmias developing after the failure of Stage 1, Preventative Trial. IV amiodarone and IV procainamide are standardly used treatment agents for the treatment of postoperative cardiac arrhythmias in this setting. The investigator will be assessing the comparative effectiveness of these agents in controlling post-operative cardiac arrhythmias. 2. To evaluate antiarrhythmic medication safety based on the frequency of SAEs and AEs

NCT ID: NCT00852488 Completed - Clinical trials for Congenital Heart Surgery

Medium-term Venous Access in Congenital Heart Surgery

Start date: March 2009
Phase: N/A
Study type: Interventional

This study is designed to evaluate medium-term central venous catheter placement in infants undergoing complex cardiac surgery using a new technique. This technique involves placement of the catheter into the inferior vena cava through a subcutaneous tunnel and through a tunnel between pericardium and diaphragm.

NCT ID: NCT00620945 Terminated - Clinical trials for Cardiopulmonary Bypass

Use of Phenoxybenzamine [PBZ] IV to Assist High Flow Low Pressure Perfusion [HFLPP] on Cardio-pulmonary Bypass

Start date: June 2006
Phase: N/A
Study type: Interventional

Cardiopulmonary bypass [CPB] in small size bodies can result in decreased peripheral perfusion. This results in anaerobic metabolism as evidenced by lactic acidosis. High flow perfusion results in systemic hypertension which is accentuated by moderate hypothermia commonly used during cardiopulmonary bypass. Phenoxybenzamine [PBZ] is an arteriolar vasodilator that acts by irreversibly blocking the alpha adrenergic receptors. It causes vasodilatation allowing high flow, low pressure CPB. It has been used extensively outside US in Canada, Europe and Australia. In the US oral PBZ is FDA approved, whereas intravenous PBZ is only available as an investigational drug

NCT ID: NCT00215072 Terminated - Clinical trials for Congenital Heart Defects

Death Following Congenital Heart Surgery

Start date: July 2005
Phase: N/A
Study type: Observational

The purpose of this study is to elucidate the patterns of death following congenital heart surgery.